{"name":"Pieris Pharmaceuticals, Inc.","slug":"pieris-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxQWTJVTGh0ejN2YjM1TlN0dzlINUI2X0dubnVSWHdzTGxaZFBRM3RqNm14LWdMWERyamxIbW1YTHZLRWhpbDhDR3dFNHIwSWxMWGZOQXBweEpPdG9qakYwNUoySzZZN0lQQlV2a1FDX0Z0ZmxDYlREY0tmSVpYYkR6YjY4OWlseUFTWmF3VG1fMElGeXNTczZsTEFFdFpOTy1JN3ZJMnd5NGFTNXpaeXRINnNkWVBTVW1zbUlwZGNROUZnR0xvcXpLcFh1dXdmMEFMUGJYU2dMNV9Zdm9VcktZMUU4WUQzZmxrcEdqVXRQT1RtbWhlS1NZYTk0WmVqWUdZakhvZGIwaVdMVU84MDAyNkVZOFhlNkRFODR5T2ZzTzQzOWpPMjF0cktlcDVZNl9Nc0hkbWc5ZldWZm1iSlVNaWx3aURiWF9lUnc?oc=5","date":"2026-03-26","type":"pipeline","source":"Barchart.com","summary":"Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma - B","headline":"Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia The","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxQbkk4RVM2cUo5VGtyaWdnc3RMSG53bUlMbEtNb2dyZHcwWEd1M3BJaGIzclhvTzFhLUJXQlJlRXpLLS15bWN5MkRWMXE4YzNxX00tZEk5ZGp2ZWtkdUduUHV0eE9wY0p0Sm5DYzZNTHd4QjdWdS1lTU5UMVo3U0tKUEl4eE5DcmhkbXhXbGRMbmxXOFN0aVJXUl9wVlRwdTJfTnMzU1hoT0VBTG4xeFA3WW1UOFJNTEJ1VEpJMmFPNlN6SDBFWXJ0bGQwN0lRaDYxX2tQZl9XOXJ6ZGp4U3Vpby1mUDhmMzFrbVMwU01ycnlWZEh3NkVMSTN6SkEyc2lzRnpKeUVFSDRRc3N1WjV1WWxKOERXSkI1cmxjVmh0VndTWjRuTmNqM095cW1Jc2pVcUFRRkU4TGFjOXN3UlBianctbUxfb1NhMWF5Z1BR?oc=5","date":"2026-03-26","type":"pipeline","source":"Barchart.com","summary":"Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma - B","headline":"Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia The","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNR29wLTRZb0FBMGRqRDV0d25jRWJDb3NlaFg5Qkc0NkRRUnFsZG1CNzdJaEZzV1JjLWxtYnVrVElHX0NfX1JyVHlFRXlHWUdWdHdLLW9qbFBIYTdEckU0SXB0b0ZYRUNZX1JWT0kzczBZN3VPakxnX1h3WlpBcGJkTDdVRlMyeGhiRDBYblllVHJaZw?oc=5","date":"2026-03-21","type":"trial","source":"openPR.com","summary":"HER2 Positive Gastric Cancer Clinical Trial Pipeline - openPR.com","headline":"HER2 Positive Gastric Cancer Clinical Trial Pipeline","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxNc1lsTmVGYmFzSGkzRXlVX2RMeDI2UlQ0VVJBVkhYMkQ1VlpaMFNCX3gtdzBwZEU5UWtUbWNPWmxhMm5jQ3AyMWtMMXhkVW9RSlM2bTNzVy1SdUt6Vmp0Wjk3T0tvUGZHQktEc1B0aTBBbUNfelU4XzFoOHZWVEdrVFpNYklZbFZNQWFDUlFhbVFaaDdYVE03VlNvdk9VczhYY2Q2Ul9KX0F3c3RKQk1QZVQxa3BuOEJOMnQ2Q1lwc3hLYkc5UEtSWm1wTVNHMVpaQ2Y1SmQ3dGljYS1aWjNIWVotRUI1T1lTLUZMb3ROenV5T2ZPOVl5cnVBV19CbTNabnRhOGQzSXhhY1pDWnBXOGFabw?oc=5","date":"2026-03-21","type":"trial","source":"Barchart.com","summary":"HER2 Positive Gastric Cancer Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com","headline":"HER2 Positive Gastric Cancer Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Ma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxOQnVMZjBIMnRadVZZWkJTZGdNU3E0YkV6blU4ZTZwbEVuV09udVJvZDEzTFRmcjhjb1NhRDctNktxUHA1SmViU0xNYVNZejhOUS1XeFJVR3A2VzQ2MjAweE9EdHJJVzhMV0cxYUM0eF9CV0drVXhwbmQ2bHF2YzE5U2M5V0I5cUhtMXdFM1NjckE1dGhXR21uMzBfeWtaWEtkMkdkZnFZd1NDc3NldFFmVndCUEF3elRtNUJGMUpkLWF0UV9ITHpTOURBVS1KY3ZTN24tMWMzMlEyaGdVUXlLZ2JFRE5wWHhUODVFRGxfQlJTSXVkeTMtclBIbXVSQjJEdGxOSHFYdmxvRmtYUDN5RDdIY1NaRmZhQlpORm1oeXo1alRXbzh6SVUzT25SUlhWN3RXMkJJX1dFS2MyTF8wVjZzVGRqNkU?oc=5","date":"2025-10-23","type":"pipeline","source":"PR Newswire","summary":"Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight - PR Newswire","headline":"Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Dia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNZGtWZHFNbTBHS1YyTU1ENWd4Y09VQ3ZPbWQ2NmZyUHlVbl8zdU5JR1hwbl9aN2xQdlNHaWNSdWV4cjlOdEhHMGVSeEtkaWlVOFN5dGRZZHRHLUN4b1dBUmFGNGVIcWhTTi1NTnNnb00yUDlkLXRzTWVtTFZyT1ozbUtGTmxlUnZzZmEwQkZXSEVIXzR1VkxDWlluLVRXR0tDdTZteTQ0V2ZFbGM3TmJjVWM1TEI4MUlHWnRCOEwydmx6YUtreVMybWJoUWxkSkZtb3dYb1VJNjVLSTdFNWotdGY1ZnlxdnNRWkt1Q2VCeGVvbVpfUWptOXlISkhNZ01FQWF3Zks5YWVJQ0FVYkVpV2x1TnVTdVpK?oc=5","date":"2025-06-09","type":"regulatory","source":"PR Newswire","summary":"HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034) | DelveInsight - PR Newswire","headline":"HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNbTZEb2F1MHF5VnhjMlM1dXBoeEEwcS1iREgyRTVIQmpzM2ZORk83dWJYSmktUFg2NllQYnlnbzRyWmVhckI5bTJBNGJaNFE1NkFEYi1nLUl6Tnd3U3FLclNXbFdlVVJtSDNGRmhnV25LdnhCVVl3a3ZxTm43SlVUWU4wZXJHMWNBOTlvTExhUzFMbGwwVEw0Sk5SWDg0V2Yyb3duTE1zcDBrMWxpeExDLXZoOTFRYXFvN3kzNnpRMmh2dVhLUkR3YkUwbGtpQmdXY1pLVTJnZFN1RUhpQk16UVBadw?oc=5","date":"2024-07-24","type":"deal","source":"ACCESS Newswire","summary":"Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement - ACCESS Newswire","headline":"Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNaEtFWlBwT1FhejZrSDVOLXhzRUhDQ1ZoNnhWb2VYbldPRTBqZTh6RU90UTJxQXFMbEZIcnM1M3dkbUxueTNfQzRFQ2Ryd04zNTRtencyQzRjc3MxbVJxUXAwUFM1ajFkMUtiSDRxa3lvZkFRV3dGTW14bjhuQ0dfMWttUWVpRjNHS3VodDU2bUJMTzQwbTlFR3BhT0dqMFJmdE02enh3RFJMRkg1MG9NSE9FTQ?oc=5","date":"2023-07-19","type":"pipeline","source":"Pharmaceutical Technology","summary":"Pieris Pharma lays off 70% of workforce amid company restructuring - Pharmaceutical Technology","headline":"Pieris Pharma lays off 70% of workforce amid company restructuring","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBaeW1KV1pWR1p6cWRTeEJyeHJUZlJxT3FwTEYyaGpNY0ktRnl4MHhFWjNPSF9qZXBTaG5DMFJnOWtqRDUydXVxNkRJbzVJaGZI?oc=5","date":"2021-09-13","type":"pipeline","source":"The Motley Fool","summary":"Pieris Pharmaceuticals - PIRS - Stock Price & News - The Motley Fool","headline":"Pieris Pharmaceuticals - PIRS - Stock Price & News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxNYXplelljeTViTTMzVFU5MjlQM2ppTFlVbHFpa2ZFMnp0VGZhZGgydjlnbDgzc3dFUjd3akMyQjhPS1Vwdkh1M0FmazBrNkRMRVRoeGZiZ2sxTUZfTzJaQnhUR0x4SHFlaFJPNmIyX2s0d0JmRlNvaVFkNi0wNGwzXzZEcWtxUkFTcnowbVBKeHdOOTNwNWsxUzUwQ3Q3RDd0YXY0U0xhS0lLM09BUEFpM24wYklqLVRuTFY2V3VBSVBpUDBkWXhOdHFOYUhQVmpPNUFZSG5fbzhwYVdZOEpmOTJXWXczRlQ0bXNxbVZpV1RSM2ZBdGlQTlRlZkhtMWVhbHIxUGlwZEZMTnVWNDhfNkFlQi1hbjVSX1Y0eVl1cWVUcmxQN1owZVNUQU1iMm5R?oc=5","date":"2021-04-26","type":"deal","source":"Business Wire","summary":"Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - Business Wire","headline":"Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPUzZwTE1JQXNFRUZBQ3czMHJQSHpnMTR3amJ2WXl2YTBrX2RfSThtc0hfOGZWdU40djFKbEo1aTF4RmxfTURwY1V2N2RxaGdFeXc0VWplT3BQWGVFcGxrUW9TWU1CNnZkRXFsYlp2OG85T3EzVGpORGFnTFFsRUVUYzMtcGhQSWFJQUtrdXlvbUJLZDQ?oc=5","date":"2018-02-09","type":"deal","source":"BioPharma Dive","summary":"SeaGen, Pieris ink deal for bispecific I/O drugs - BioPharma Dive","headline":"SeaGen, Pieris ink deal for bispecific I/O drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxPaUZvblRPZXNaY094TlhzN3FoR3JiQ2NKc2oyMkJjYzVzejV2b1FvVk5hZl9aMmVjRFl6TFloVGJZWUh4X2NIM2RzN0NveF9TOGRHWEFRUlJibmdnMEFhOWhGbl9heWV5R1picXd3QjN6SUpvTzRKMkZwc3dfRWRzd2U2Xy04WEg4X2RwMW9vVzBUamFFRlVUZU9xRzltNFdxUTFGbHFaVkk3NktncjNiQk1LUXJUVjdQYUFCWnNpcnVRc3Z4RXcxNXR3QkJBdmZjMU4tMGRlbEFxdTJNOHdPUUFwbHRCQTZpLVF0aXh1U2t1MHAxMFB2NG9ESUJFLUZBQk9TbGhpTlF1NDYwUEh1ZUVuTDBpN0NsQWRxZmR0LUlhUlhwMXA2R1h5UHh5MVNETjF4bjFoYUNmdw?oc=5","date":"2017-05-03","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca and Pieris Pharmaceuticals collaborate to develop and commercialise Anticalin-based inhaled treatments for respiratory diseases - AstraZeneca","headline":"AstraZeneca and Pieris Pharmaceuticals collaborate to develop and commercialise Anticalin-based inhaled treatments for r","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}